InflaRx N.V.  (NASDAQ:IFRX) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed vilobelimab for SARS-CoV-2-induced acute respiratory distress.

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the ...

The full indication for vilobelimab is as a treatment for adult patients with SARS‑CoV-2‑induced ARDS who are receiving ...

In conclusion, the findings of this study provide evidence that glucocorticoid treatment-induced down-regulation of systemic inflammation in ARDS is associated with a significant improvement in ...

High blood pressure often develops silently, earning its reputation as a dangerous yet stealthy health condition. While early ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The Company’s drug ...

Supportive treatment for restrictive and obstructive lung diseases can include supplemental ... National Heart, Lung, and Blood Institute. Acute Respiratory Distress Syndrome. National Organization ...

A record number of women were waiting for a gynaecology appointment in Lisburn and Castlereagh and Ards and North Down, new ...